Cannabis Use in Older Adults

Not medical advice

This article is not medical advice. It summarizes published evidence for educational purposes. Older adults often take multiple medications, have conditions that affect drug metabolism, and face higher risks from sedating substances. If you are considering cannabis — or already using it — talk to a clinician who knows your full medication list. Bring the actual product label. 'Natural' does not mean 'safe with your other prescriptions.'

Plain-language summary

People over 65 are the fastest-growing demographic of cannabis users in North America. Use among adults 65+ in the United States roughly quadrupled between 2007 and 2017, and has kept climbing since ^[1][2]. Most older users are not chasing a high — surveys consistently show they're treating pain, insomnia, anxiety, or side effects of cancer treatment ^[3].

The short version of the evidence:

• Probably helps: chronic pain (modestly), chemotherapy-induced nausea, some appetite loss.
• Might help: sleep onset, certain spasticity symptoms.
• Probably doesn't help much: dementia-related agitation, depression, glaucoma (despite old folklore).
• Comes with real costs: sedation, falls, confusion, drug interactions, cardiovascular strain, and — in a small minority — psychiatric reactions.

Older adults are more sensitive to THC than younger adults at the same dose ^[4]. The standard geriatric prescribing principle — start low, go slow — applies doubly here.

What probably works

Chronic non-cancer pain. The 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) review concluded there is substantial evidence that cannabis or cannabinoids reduce chronic pain in adults Strong evidence^[5]. Effect sizes are modest — comparable to or slightly smaller than other adjunctive therapies — and most trials used pharmaceutical cannabinoids (nabiximols, dronabinol) rather than smoked flower. Real-world observational studies in older adults report pain reductions and decreased opioid use, but these are not controlled trials Weak / limited^[6].

Chemotherapy-induced nausea and vomiting. Dronabinol (synthetic THC) and nabilone have FDA approval for this and decades of supporting trials Strong evidence^[5]. They're typically second- or third-line after modern antiemetics like ondansetron.

Appetite stimulation in wasting syndromes. Evidence for dronabinol in HIV-associated and cancer-associated weight loss is reasonable, though modern protocols have moved on in many cases Strong evidence^[5].

Multiple sclerosis spasticity. Nabiximols (Sativex) has moderate evidence for patient-reported spasticity, though objective measures show smaller effects Strong evidence^[5]. This matters in older MS patients but isn't a typical geriatric indication.

What might work

Sleep. Many older users report cannabis helps them fall asleep. Controlled evidence is thin and mixed: short-term studies show modest reductions in sleep latency, but long-term use is associated with reduced slow-wave and REM sleep, and tolerance develops Weak / limited^[5][7]. THC-dominant products may help initiation; they are not a clean substitute for treating underlying sleep apnea, restless legs, or depression.

Anxiety. Low-dose THC and CBD have shown anxiolytic effects in some experimental settings, but high-dose THC reliably produces anxiety in many users — a U-shaped curve Weak / limited^[8]. For older adults sensitive to THC, this is a real risk.

Dementia-related agitation. Small trials of dronabinol and nabilone in agitated dementia patients have shown some reduction in agitation scores, but samples are tiny and dropout is high Weak / limited^[9]. This is not the same as 'cannabis treats Alzheimer's,' which is a common marketing overreach.

Parkinson's disease. Patient surveys report symptom relief, but controlled trials are small, inconsistent, and mostly negative for motor symptoms Disputed^[10].

What doesn't work or has weak evidence

• Glaucoma: Cannabis lowers intraocular pressure briefly, but the effect is too short-lived to be useful, and the American Academy of Ophthalmology explicitly recommends against it Strong evidence^[11].
• Curing or slowing dementia: No human clinical evidence. Preclinical mouse and cell-culture studies do not translate to clinical recommendations No data.
• Depression: No good evidence cannabis treats depression; some longitudinal data suggest heavy use is associated with worse mood outcomes Weak / limited^[5].
• Cancer treatment (not symptom relief): Despite widespread anecdotal claims, there is no clinical trial evidence that cannabis cures or shrinks cancers in humans No data^[12].

What we don't know

• Long-term cognitive effects of regular cannabis use starting after age 65. Most cognitive data come from people who used heavily as adolescents or young adults.
• Optimal dosing in frail older adults. Pharmacokinetic studies in this population are sparse.
• Whether CBD-dominant products meaningfully help any geriatric condition. Most rigorous CBD evidence comes from pediatric epilepsy syndromes at doses (10–20 mg/kg/day) far higher than what's in consumer products.
• Interactions with the long list of common geriatric medications (anticoagulants, antihypertensives, antidepressants). Mechanistic concerns are well-established; clinical outcome data are not Weak / limited^[13].

Comparison with standard treatments

For chronic pain, cannabis is generally less effective than NSAIDs or duloxetine for inflammatory and neuropathic pain in head-to-head terms, but it has a different side-effect profile and may help when those fail. It is not equivalent to opioids in potency, but it also carries far lower overdose risk. The Canadian and Israeli systems have used it as an adjunct, not a replacement Weak / limited^[6].

For sleep, cognitive behavioral therapy for insomnia (CBT-I) has stronger and more durable evidence than any pharmacologic option, including cannabis Strong evidence^[14]. Among drugs, low-dose doxepin and melatonin have cleaner safety profiles in older adults than THC.

For nausea, modern antiemetics (5-HT3 antagonists like ondansetron, NK1 antagonists like aprepitant) are first-line. Cannabinoids are useful add-ons for refractory cases Strong evidence^[5].

Risks specific to older adults

Falls and injury. THC impairs balance and reaction time. Older adults already at fall risk see this risk amplified Strong evidence^[4]. ER visits for cannabis-related injuries in adults 65+ have risen sharply in legal states ^[15].

Cardiovascular. THC raises heart rate and blood pressure acutely. Case-control and cohort data link cannabis use to elevated risk of myocardial infarction and stroke, particularly with heavy use Weak / limited^[16]. Older adults with coronary disease should be cautious.

Cognition. Acute intoxication impairs memory, attention, and executive function. Older adults appear more sensitive at lower doses than younger adults Strong evidence^[4]. This can be mistaken for dementia progression.

Drug interactions. Cannabinoids are metabolized by CYP3A4 and CYP2C9 and inhibit several CYP enzymes themselves. Documented or plausible interactions include warfarin (raised INR), clobazam, tacrolimus, and many statins and SSRIs Strong evidence^[13].

Psychiatric. High-THC products can trigger acute anxiety, paranoia, or — rarely — psychosis, especially in cannabis-naive older users who underestimate edible potency.

Cannabis hyperemesis syndrome. A paradoxical cyclic vomiting condition in chronic heavy users; underrecognized in older adults and frequently misdiagnosed Strong evidence^[17].

See also: Cannabis and Drug Interactions, Edibles Dosing Guide, THC vs CBD.

Sources

How this page was made

Related

• Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...